Literature DB >> 25336620

The Biobanking Analysis Resource Catalogue (BARCdb): a new research tool for the analysis of biobank samples.

Joakim Galli1, Johan Oelrich2, Michael J Taussig3, Ulrika Andreasson4, Eva Ortega-Paino4, Ulf Landegren2.   

Abstract

We report the development of a new database of technology services and products for analysis of biobank samples in biomedical research. BARCdb, the Biobanking Analysis Resource Catalogue, is a freely available web resource, listing expertise and molecular resource capabilities of research centres and biotechnology companies. The database is designed for researchers who require information on how to make best use of valuable biospecimens from biobanks and other sample collections, focusing on the choice of analytical techniques and the demands they make on the type of samples, pre-analytical sample preparation and amounts needed. BARCdb has been developed as part of the Swedish biobanking infrastructure (BBMRI.se), but now welcomes submissions from service providers throughout Europe. BARCdb can help match resource providers with potential users, stimulating transnational collaborations and ensuring compatibility of results from different labs. It can promote a more optimal use of European resources in general, both with respect to standard and more experimental technologies, as well as for valuable biobank samples. This article describes how information on service and reagent providers of relevant technologies is made available on BARCdb, and how this resource may contribute to strengthening biomedical research in academia and in the biotechnology and pharmaceutical industries.
© The Author(s) 2014. Published by Oxford University Press on behalf of Nucleic Acids Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25336620      PMCID: PMC4383877          DOI: 10.1093/nar/gku1008

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   19.160


INTRODUCTION

Biobanks are recognised as invaluable resources for clinical research and are being increasingly used for basic medical research, biomarker discovery, personalised medicine and drug development—indeed wherever sets of well annotated human samples are required. Biobanking activities have increased considerably during the recent decade (1,2). In Europe, initiatives such as BBMRI (the Biobanking and Biomolecular Resources Infrastructure, http://www.bbmri.eu), as well as corresponding national initiatives in Scandinavia and throughout Europe, have sought to coordinate the availability of samples in biobanks (3). Furthermore, these initiatives encompass not only the storage, handling and pre-analytical aspects, as in the U.S. guidelines Biospecimen Reporting for Improved Study Quality (4), but they also provide up-to-date information about methods (‘biomolecular resources’) which can be applied to them. Indeed, biobanks, molecular technologies and reagents for molecular analyses represent a trinity of crucial resources: for optimal function it is necessary to achieve excellence in all three areas in order to take full advantage of opportunities for studies of patient sample collections. The recent rapid development of high throughput techniques for molecular analysis, including genomics (Single Nucleotide Polymorphism (SNP) typing and exome, whole genome and epigenome sequencing), transcriptomics, proteomics, metabolomics and imaging techniques for tissues and cells, has vastly expanded opportunities to collect large amounts of data that offer valuable insights into the aetiology and progress of diseases, as well as enabling identification of biomarkers for disease stratification, prediction and early diagnosis. The central contribution of biobank samples for genetic studies is evident in, e.g. sequencing surveys of cancer genomes (5) and genome-wide association studies (6), while in the protein field there is a particular demand for sensitive and multiplex methods for determination of biomarkers in patient tissue and plasma samples (7), especially in longitudinal studies, and for autoantibody detection in patient cohorts (8). It is therefore of particular importance to ensure that researchers have broad access to state of the art—and in particular to beyond state of the art—techniques and reagents, in order to ensure that the maximal potential of biobank samples is realised. This efficient connection between techniques, samples and medical questions is also critically important for innovators of molecular techniques. However, it is often difficult to identify suitable technology providers to undertake studies with the required level of throughput and standardisation. In response to this need, we have designed an online database, termed BARCdb (Biobanking Analysis Resource Catalogue), as a freely available resource of information to facilitate optimal use of samples stored in biobanks. BARCdb provides up-to-date information on technologies and reagents for analysis of biobank samples, together with listings of service providers and relevant organisations, together with details of services offered, location and contact information. Initially focused on facilities in the Nordic region as part of the Swedish BBMRI network (http://www.bbmri.se), BARCdb is now being extended to the rest of Europe.

COMPUTATIONAL DESIGN

BARCdb has been built using the MVC (Model, View, Controller) design pattern, with these three aspects implemented as separate entities. The purpose is to facilitate maintenance and further development as well as testing. The system is implemented in the C# programming language and uses Microsoft ASP.NET, Entity Framework and ASP.NET. MVC. ASP.NET is a large collection of web-related libraries; Entity Framework helps with the database design and the mapping of database entries to types used by the BARCdb application; ASP.NET MVC is an implementation of the MVC design pattern in ASP.NET. The front end of the system is enhanced with JavaScript and CSS. To render BARCdb easier to use, some pages have been built using suggestions from the SPA (Single Page Application) pattern. An example is the front page where the layout is altered depending on what the user does.

DATABASE AND SEARCH FUNCTIONS

BARCdb presents resource and provider information in the form of ‘resource cards,’ which summarise the services available at each site and the contact details (Figure 1). Each card can be expanded with a click to provide more details. Specifications for sample requirements are included on the card, such as which types of samples can be analysed, recommended assay format, minimal sample volume, analysis throughput, and cost. The database can be searched either by free text or by categories, i.e. genomics, proteomics, metabolomics, imaging, bioinformatics and biomolecular resources. The search can also be refined by geographical location, resource type, database, product or service.
Figure 1.

The BARCdb webpage showing (A) the home page and (B) a search result for next generation DNA sequencing resources. Individual cards function as links to more details of the analysis resource.

The BARCdb webpage showing (A) the home page and (B) a search result for next generation DNA sequencing resources. Individual cards function as links to more details of the analysis resource.

EXAMPLES OF TECHNOLOGIES FOR BIOBANK SAMPLES

Table 1 summarise the number of resources currently included in BARCdb (October 2014). Not surprisingly perhaps, many of the providers specialise in DNA sequencing and related genome analysis. Supplementary Tables S1–S4 in the supporting material (online-only content) list all providers included. Specific examples of methods that are offered to users are:
Table 1.

Present number of BARCdb analysis resources cards (October 2014)

Analysis resource typeNumber
Genotyping and gene expression analysis (microarrays)30
Next Generation DNA sequencing27
Next Generation DNA sequencing support8
Sanger DNA sequencing6
High-throughput DNA extraction5
Metabolomics12
Proteomics, affinity-based17
Proteomics, mass spec-based19
Imaging8
Other11
Total143
Array based technologies for genotyping and gene expression measurements Next generation DNA sequencing Protein analysis technologies, including both mass spectrometry and affinity-based methods Metabolomics by mass spectrometry and NMR Bioinformatics resources for analysis of data from next generation DNA sequencing, array-based gene expression, mass spectrometry, antibody-based protein biomarker analysis, etc.

SERVICE PROVIDER SUBMISSION PROCESS AND UPDATES

Content within BARCdb is continuously expanded and new resource providers, whether part of academic centres or companies, are invited to participate in the catalogue. An online questionnaire has been set up at http://www.barcdb.org for potential new providers. The data from the questionnaire are uploaded and a personal account is created for each provider with the possibility to update the resource information at any time. The intention is to gather information on resources for sample analysis in order to create a comprehensive Europe-wide coverage. Thus, BARCdb can be utilised by service providers to attract new customers, while for researchers it provides insights into technologies and their providers, as well as opportunities for new collaborations. The usage of the database is steadily increasing and presently the number of monthly active users is around 200 with 2000 page views.

DISCUSSION

Biological samples are used in high-throughput techniques that allow examination of differences among individuals and over time in genomes, transcriptomes, proteomes or metabolomes and their relation, if any, to medical conditions. In addition to the significance of the data per se, insights derived from the analyses are also expected to drive the development of new diagnostic, prognostic and therapeutic tools, devices, reagents and drugs. Consequently, biological resources, of which the specimens stored in biobanks are a prime example, are essential raw materials for the advancement of basic life science research, biotechnology and human health. By ensuring that advanced, in some cases unique, and emerging methods are put to early and efficient use with high-quality biobank samples, scientific progress as well as commercial application by biotechnology, diagnostic and pharmaceutical industries will be promoted. Among the anticipated commercial benefits are the identification of new disease biomarkers and drug targets, together with a generally enhanced understanding of disease mechanisms. With these broad aims in mind, we have introduced the BARCdb database as a resource for users of biobank samples searching for technologies and technology providers. BARCdb aims to fulfil an unmet need by making available, in a readily accessible form, information on molecular analysis resources and services and how and where they can be obtained, something that is not always easy to find elsewhere. The BARCdb search functions allow users to focus directly on the technologies they wish to obtain, giving researchers ‘one-stop-shop’ access to resources. While the construction of BARCdb has been initiated within the Swedish biobanking infrastructure BBMRI.se, the resource can fulfil an important role in several EU level infrastructures within the European Strategy Forum on Research Infrastructures (ESFRI). In particular, besides the European level BBMRI, the two infrastructures EATRIS, having a focus on translational research, and ECRIN, devoted to clinical research, also depend on shared technology resources and standards, and can greatly benefit from a resource such as BARCdb. Recently, the emerging concept of BBMRI Expert Centres has been proposed as a novel public-private partnership model stimulating transnational research collaborations (9). Expert Centres will encompass regions able to provide world-class biobanks, technology resources and medical expertise. At the request of academic scientists, major pharmaceutical firms or the diagnostic industry, such centres would undertake analyses of samples in the country of origin under internationally standardised conditions. The data would then be made available to the academic or industrial partner for further development. This can circumvent the many restrictions of exporting biological samples across borders, which otherwise makes transnational research collaboration difficult. It is intended that BARCdb will also serve as a repository of information on Expert Centres. Another future aim for the BARCdb database is to include not only information about the methodology used by the service providers, but also whether (and if so which) standardised procedures are followed. This can be enabled by references in BARCdb to carefully documented standard operating procedures (SOPs). Such SOPs can be provided via another linked database, MolMeth (http://www.molmeth.org), which allows users to see how analyses are performed and whether data produced at different sites are generated under conditions that allow comparison of results. Increasingly, biobank related research needs to build upon patient samples collected across many different research centres in several countries. This need for ever larger studies is a direct consequence of the increasing number of molecular factors being evaluated, necessitating stronger statistical support, as well the need for replicating observations in new cohorts and across different populations. Taken together, the standardisation made possible by these databases can play an important role in supporting such international cooperation. Samples are being collected with the intention of being used over many years, whereas technologies for analysis can be expected to improve rapidly and radically. BARCdb can help reconcile these conflicting aims by advising on foreseeable needs for sample types, thus improving the value, and accessible information content of the biobank samples being collected. Challenges in developing BARCdb further and establishing its usefulness include the wide dissemination of technology information to users of biobank samples throughout Europe, understanding user requirements and guiding the users to the most relevant analytical and pre-analytical methods out of the many possibilities available. We plan to complement the entries in the database with short reports detailing pros and cons of different techniques that may be considered for a given application. The need to keep abreast of advances in existing technologies and introduction of new technologies as they arise will also create a requirement to continuously update the database information by identifying new providers in both the academic and commercial spheres. The increased volume of data provided by DNA sequencing and other high throughput methods will also provide a constant challenge for computing and bioinformatics resources. The provision of services in this area will be of increasing importance to the biobanking community. By maintaining a wide, up-to-date coverage of technologies and providers, BARCdb can provide an important service to researchers using samples from Europe's biobanks to advance understanding, diagnostics and therapy of disease.

SUPPLEMENTARY DATA

Supplementary Data are available at NAR Online.
  9 in total

Review 1.  Five years of GWAS discovery.

Authors:  Peter M Visscher; Matthew A Brown; Mark I McCarthy; Jian Yang
Journal:  Am J Hum Genet       Date:  2012-01-13       Impact factor: 11.025

2.  Biorepositories: Building better biobanks.

Authors:  Monya Baker
Journal:  Nature       Date:  2012-06-06       Impact factor: 49.962

3.  Introduction to special issue for biobanks and biorepositories.

Authors:  Catherine A Hammett-Stabler; Nichole Korpi-Steiner
Journal:  Clin Biochem       Date:  2014-01-15       Impact factor: 3.281

4.  Biospecimen reporting for improved study quality (BRISQ).

Authors:  Helen M Moore; Andrea B Kelly; Scott D Jewell; Lisa M McShane; Douglas P Clark; Renata Greenspan; Daniel F Hayes; Pierre Hainaut; Paula Kim; Elizabeth Mansfield; Olga Potapova; Peter Riegman; Yaffa Rubinstein; Edward Seijo; Stella Somiari; Peter Watson; Heinz-Ulrich Weier; Claire Zhu; Jim Vaught
Journal:  J Proteome Res       Date:  2011-06-21       Impact factor: 4.466

Review 5.  Human biological sample biobanking to support tissue biomarkers in pharmaceutical research and development.

Authors:  Christopher Womack; S Rachel Mager
Journal:  Methods       Date:  2014-01-30       Impact factor: 3.608

6.  Comprehensive catalog of European biobanks.

Authors:  H-Erich Wichmann; Klaus A Kuhn; Melanie Waldenberger; Dominik Schmelcher; Simone Schuffenhauer; Thomas Meitinger; Sebastian H R Wurst; Gregor Lamla; Isabel Fortier; Paul R Burton; Leena Peltonen; Markus Perola; Andres Metspalu; Peter Riegman; Ulf Landegren; Michael J Taussig; Jan-Eric Litton; Martin N Fransson; Johann Eder; Anne Cambon-Thomsen; Jasper Bovenberg; Georges Dagher; Gert-Jan van Ommen; Michael Griffith; Martin Yuille; Kurt Zatloukal
Journal:  Nat Biotechnol       Date:  2011-09-08       Impact factor: 54.908

7.  International network of cancer genome projects.

Authors:  Thomas J Hudson; Warwick Anderson; Axel Artez; Anna D Barker; Cindy Bell; Rosa R Bernabé; M K Bhan; Fabien Calvo; Iiro Eerola; Daniela S Gerhard; Alan Guttmacher; Mark Guyer; Fiona M Hemsley; Jennifer L Jennings; David Kerr; Peter Klatt; Patrik Kolar; Jun Kusada; David P Lane; Frank Laplace; Lu Youyong; Gerd Nettekoven; Brad Ozenberger; Jane Peterson; T S Rao; Jacques Remacle; Alan J Schafer; Tatsuhiro Shibata; Michael R Stratton; Joseph G Vockley; Koichi Watanabe; Huanming Yang; Matthew M F Yuen; Bartha M Knoppers; Martin Bobrow; Anne Cambon-Thomsen; Lynn G Dressler; Stephanie O M Dyke; Yann Joly; Kazuto Kato; Karen L Kennedy; Pilar Nicolás; Michael J Parker; Emmanuelle Rial-Sebbag; Carlos M Romeo-Casabona; Kenna M Shaw; Susan Wallace; Georgia L Wiesner; Nikolajs Zeps; Peter Lichter; Andrew V Biankin; Christian Chabannon; Lynda Chin; Bruno Clément; Enrique de Alava; Françoise Degos; Martin L Ferguson; Peter Geary; D Neil Hayes; Thomas J Hudson; Amber L Johns; Arek Kasprzyk; Hidewaki Nakagawa; Robert Penny; Miguel A Piris; Rajiv Sarin; Aldo Scarpa; Tatsuhiro Shibata; Marc van de Vijver; P Andrew Futreal; Hiroyuki Aburatani; Mónica Bayés; David D L Botwell; Peter J Campbell; Xavier Estivill; Daniela S Gerhard; Sean M Grimmond; Ivo Gut; Martin Hirst; Carlos López-Otín; Partha Majumder; Marco Marra; John D McPherson; Hidewaki Nakagawa; Zemin Ning; Xose S Puente; Yijun Ruan; Tatsuhiro Shibata; Michael R Stratton; Hendrik G Stunnenberg; Harold Swerdlow; Victor E Velculescu; Richard K Wilson; Hong H Xue; Liu Yang; Paul T Spellman; Gary D Bader; Paul C Boutros; Peter J Campbell; Paul Flicek; Gad Getz; Roderic Guigó; Guangwu Guo; David Haussler; Simon Heath; Tim J Hubbard; Tao Jiang; Steven M Jones; Qibin Li; Nuria López-Bigas; Ruibang Luo; Lakshmi Muthuswamy; B F Francis Ouellette; John V Pearson; Xose S Puente; Victor Quesada; Benjamin J Raphael; Chris Sander; Tatsuhiro Shibata; Terence P Speed; Lincoln D Stein; Joshua M Stuart; Jon W Teague; Yasushi Totoki; Tatsuhiko Tsunoda; Alfonso Valencia; David A Wheeler; Honglong Wu; Shancen Zhao; Guangyu Zhou; Lincoln D Stein; Roderic Guigó; Tim J Hubbard; Yann Joly; Steven M Jones; Arek Kasprzyk; Mark Lathrop; Nuria López-Bigas; B F Francis Ouellette; Paul T Spellman; Jon W Teague; Gilles Thomas; Alfonso Valencia; Teruhiko Yoshida; Karen L Kennedy; Myles Axton; Stephanie O M Dyke; P Andrew Futreal; Daniela S Gerhard; Chris Gunter; Mark Guyer; Thomas J Hudson; John D McPherson; Linda J Miller; Brad Ozenberger; Kenna M Shaw; Arek Kasprzyk; Lincoln D Stein; Junjun Zhang; Syed A Haider; Jianxin Wang; Christina K Yung; Anthony Cros; Anthony Cross; Yong Liang; Saravanamuttu Gnaneshan; Jonathan Guberman; Jack Hsu; Martin Bobrow; Don R C Chalmers; Karl W Hasel; Yann Joly; Terry S H Kaan; Karen L Kennedy; Bartha M Knoppers; William W Lowrance; Tohru Masui; Pilar Nicolás; Emmanuelle Rial-Sebbag; Laura Lyman Rodriguez; Catherine Vergely; Teruhiko Yoshida; Sean M Grimmond; Andrew V Biankin; David D L Bowtell; Nicole Cloonan; Anna deFazio; James R Eshleman; Dariush Etemadmoghadam; Brooke B Gardiner; Brooke A Gardiner; James G Kench; Aldo Scarpa; Robert L Sutherland; Margaret A Tempero; Nicola J Waddell; Peter J Wilson; John D McPherson; Steve Gallinger; Ming-Sound Tsao; Patricia A Shaw; Gloria M Petersen; Debabrata Mukhopadhyay; Lynda Chin; Ronald A DePinho; Sarah Thayer; Lakshmi Muthuswamy; Kamran Shazand; Timothy Beck; Michelle Sam; Lee Timms; Vanessa Ballin; Youyong Lu; Jiafu Ji; Xiuqing Zhang; Feng Chen; Xueda Hu; Guangyu Zhou; Qi Yang; Geng Tian; Lianhai Zhang; Xiaofang Xing; Xianghong Li; Zhenggang Zhu; Yingyan Yu; Jun Yu; Huanming Yang; Mark Lathrop; Jörg Tost; Paul Brennan; Ivana Holcatova; David Zaridze; Alvis Brazma; Lars Egevard; Egor Prokhortchouk; Rosamonde Elizabeth Banks; Mathias Uhlén; Anne Cambon-Thomsen; Juris Viksna; Fredrik Ponten; Konstantin Skryabin; Michael R Stratton; P Andrew Futreal; Ewan Birney; Ake Borg; Anne-Lise Børresen-Dale; Carlos Caldas; John A Foekens; Sancha Martin; Jorge S Reis-Filho; Andrea L Richardson; Christos Sotiriou; Hendrik G Stunnenberg; Giles Thoms; Marc van de Vijver; Laura van't Veer; Fabien Calvo; Daniel Birnbaum; Hélène Blanche; Pascal Boucher; Sandrine Boyault; Christian Chabannon; Ivo Gut; Jocelyne D Masson-Jacquemier; Mark Lathrop; Iris Pauporté; Xavier Pivot; Anne Vincent-Salomon; Eric Tabone; Charles Theillet; Gilles Thomas; Jörg Tost; Isabelle Treilleux; Fabien Calvo; Paulette Bioulac-Sage; Bruno Clément; Thomas Decaens; Françoise Degos; Dominique Franco; Ivo Gut; Marta Gut; Simon Heath; Mark Lathrop; Didier Samuel; Gilles Thomas; Jessica Zucman-Rossi; Peter Lichter; Roland Eils; Benedikt Brors; Jan O Korbel; Andrey Korshunov; Pablo Landgraf; Hans Lehrach; Stefan Pfister; Bernhard Radlwimmer; Guido Reifenberger; Michael D Taylor; Christof von Kalle; Partha P Majumder; Rajiv Sarin; T S Rao; M K Bhan; Aldo Scarpa; Paolo Pederzoli; Rita A Lawlor; Massimo Delledonne; Alberto Bardelli; Andrew V Biankin; Sean M Grimmond; Thomas Gress; David Klimstra; Giuseppe Zamboni; Tatsuhiro Shibata; Yusuke Nakamura; Hidewaki Nakagawa; Jun Kusada; Tatsuhiko Tsunoda; Satoru Miyano; Hiroyuki Aburatani; Kazuto Kato; Akihiro Fujimoto; Teruhiko Yoshida; Elias Campo; Carlos López-Otín; Xavier Estivill; Roderic Guigó; Silvia de Sanjosé; Miguel A Piris; Emili Montserrat; Marcos González-Díaz; Xose S Puente; Pedro Jares; Alfonso Valencia; Heinz Himmelbauer; Heinz Himmelbaue; Victor Quesada; Silvia Bea; Michael R Stratton; P Andrew Futreal; Peter J Campbell; Anne Vincent-Salomon; Andrea L Richardson; Jorge S Reis-Filho; Marc van de Vijver; Gilles Thomas; Jocelyne D Masson-Jacquemier; Samuel Aparicio; Ake Borg; Anne-Lise Børresen-Dale; Carlos Caldas; John A Foekens; Hendrik G Stunnenberg; Laura van't Veer; Douglas F Easton; Paul T Spellman; Sancha Martin; Anna D Barker; Lynda Chin; Francis S Collins; Carolyn C Compton; Martin L Ferguson; Daniela S Gerhard; Gad Getz; Chris Gunter; Alan Guttmacher; Mark Guyer; D Neil Hayes; Eric S Lander; Brad Ozenberger; Robert Penny; Jane Peterson; Chris Sander; Kenna M Shaw; Terence P Speed; Paul T Spellman; Joseph G Vockley; David A Wheeler; Richard K Wilson; Thomas J Hudson; Lynda Chin; Bartha M Knoppers; Eric S Lander; Peter Lichter; Lincoln D Stein; Michael R Stratton; Warwick Anderson; Anna D Barker; Cindy Bell; Martin Bobrow; Wylie Burke; Francis S Collins; Carolyn C Compton; Ronald A DePinho; Douglas F Easton; P Andrew Futreal; Daniela S Gerhard; Anthony R Green; Mark Guyer; Stanley R Hamilton; Tim J Hubbard; Olli P Kallioniemi; Karen L Kennedy; Timothy J Ley; Edison T Liu; Youyong Lu; Partha Majumder; Marco Marra; Brad Ozenberger; Jane Peterson; Alan J Schafer; Paul T Spellman; Hendrik G Stunnenberg; Brandon J Wainwright; Richard K Wilson; Huanming Yang
Journal:  Nature       Date:  2010-04-15       Impact factor: 49.962

8.  BBMRI-ERIC as a resource for pharmaceutical and life science industries: the development of biobank-based Expert Centres.

Authors:  Gert-Jan B van Ommen; Outi Törnwall; Christian Bréchot; Georges Dagher; Joakim Galli; Kristian Hveem; Ulf Landegren; Claudio Luchinat; Andres Metspalu; Cecilia Nilsson; Ove V Solesvik; Markus Perola; Jan-Eric Litton; Kurt Zatloukal
Journal:  Eur J Hum Genet       Date:  2014-11-19       Impact factor: 4.246

9.  Autoantibody profiling for lung cancer screening longitudinal retrospective analysis of CT screening cohorts.

Authors:  Kourtney Trudgen; Nada H Khattar; Eric Bensadoun; Susanne Arnold; Arnold J Stromberg; Edward A Hirschowitz
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

  9 in total
  1 in total

Review 1.  Has the biobank bubble burst? Withstanding the challenges for sustainable biobanking in the digital era.

Authors:  Don Chalmers; Dianne Nicol; Jane Kaye; Jessica Bell; Alastair V Campbell; Calvin W L Ho; Kazuto Kato; Jusaku Minari; Chih-Hsing Ho; Colin Mitchell; Fruzsina Molnár-Gábor; Margaret Otlowski; Daniel Thiel; Stephanie M Fullerton; Tess Whitton
Journal:  BMC Med Ethics       Date:  2016-07-12       Impact factor: 2.652

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.